Related references
Note: Only part of the references are listed.Prognostic value of programmed death ligand 1 (PD-L1) in glioblastoma: a systematic review, meta-analysis and validation based on dataset
Huan Wang et al.
BIOENGINEERED (2021)
Expression and Prognostic Value of the Immune Checkpoints Galectin-9 and PD-L1 in Glioblastomas
Arnon Moldrup Knudsen et al.
JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY (2021)
A risk signature of four aging-related genes has clinical prognostic value and is associated with a tumor immune microenvironment in glioma
Haitao Luo et al.
Aging-US (2021)
The 2021 WHO Classification of Tumors of the Central Nervous System: a summary
David N. Louis et al.
NEURO-ONCOLOGY (2021)
EGFR-ERK pathway regulates CSN6 to contribute to PD-L1 expression in glioblastoma
Lingrui Su et al.
MOLECULAR CARCINOGENESIS (2020)
Identification of immunologic subtype and prognosis of GBM based on TNFSF14 and immune checkpoint gene expression profiling
Shengrong Long et al.
AGING-US (2020)
PD-L1-Mediated Immunosuppression in Glioblastoma Is Associated With the Infiltration and M2-Polarization of Tumor-Associated Macrophages
Zhiyuan Zhu et al.
FRONTIERS IN IMMUNOLOGY (2020)
Programmed Death Ligand 1 Is a Negative Prognostic Marker in Recurrent Isocitrate Dehydrogenase-Wildtype Glioblastoma
Drew Pratt et al.
NEUROSURGERY (2019)
Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer
M. D. Hellmann et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Prognostic relevance of programmed cell death ligand 1 expression in glioblastoma
Kyu Sang Lee et al.
JOURNAL OF NEURO-ONCOLOGY (2018)
Immunotherapies for malignant glioma
Vassiliki A. Boussiotis et al.
ONCOGENE (2018)
IDO1 Inhibition Synergizes with Radiation and PD-1 Blockade to Durably Increase Survival Against Advanced Glioblastoma
Erik Ladomersky et al.
CLINICAL CANCER RESEARCH (2018)
Immune checkpoint therapy in liver cancer
Feng Xu et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2018)
Multidimensional communication in the microenvirons of glioblastoma
Marike L. Broekman et al.
NATURE REVIEWS NEUROLOGY (2018)
Correlation between lower balance of Th2 helper T-cells and expression of PD-L1/PD-1 axis genes enables prognostic prediction in patients with glioblastoma
Yasuo Takashima et al.
Oncotarget (2018)
Predictors of Response to Autologous Dendritic Cell Therapy in Glioblastoma Multiforme
Chia-Ing Jan et al.
FRONTIERS IN IMMUNOLOGY (2018)
Nobel committee honors tumor immunologists
Anand Rotte et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2018)
Cancer immunologists scoop medicine Nobel prize
Heidi Ledford et al.
NATURE (2018)
Combination Therapy with Anti-PD-1, Anti-TIM-3, and Focal Radiation Results in Regression of Murine Gliomas
Jennifer E. Kim et al.
CLINICAL CANCER RESEARCH (2017)
Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
J. D. Wolchok et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Relationship between expression of PD-L1 and tumor angiogenesis, proliferation, and invasion in glioma
Song Xue et al.
ONCOTARGET (2017)
Comprehensive analysis of PD-L1 expression in glioblastoma multiforme
Dieter Henrik Heiland et al.
ONCOTARGET (2017)
Retrospective review of safety and efficacy of programmed cell death-1 inhibitors in refractory high grade gliomas
Samantha N. Reiss et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2017)
PD-L1 Expression and Combined Status of PD-L1/PD-1-Positive Tumor Infiltrating Mononuclear Cell Density Predict Prognosis in Glioblastoma Patients
Jiheun Han et al.
JOURNAL OF PATHOLOGY AND TRANSLATIONAL MEDICINE (2017)
PD-L1 expression and prognostic impact in glioblastoma
Edjah K. Nduom et al.
NEURO-ONCOLOGY (2016)
Theory Meets Practice for Immune Checkpoint Blockade in Small-Cell Lung Cancer
Jonathan W. Riess et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Expression of programmed cell death-ligand 1 and its correlation with clinical outcomes in gliomas
Jing Zeng et al.
ONCOTARGET (2016)
Molecular and clinical characterization of PD-L1 expression at transcriptional level via 976 samples of brain glioma
Zheng Wang et al.
OncoImmunology (2016)
Nivolumab and pembrolizumab as immune-modulating monoclonal antibodies targeting the PD-1 receptor to treat melanoma
Elnaz Faghfuri et al.
EXPERT REVIEW OF ANTICANCER THERAPY (2015)
Immune Checkpoint Blockade Therapy: The 2014 Tang Prize in Biopharmaceutical Science
Ya-Shan Chen et al.
BIOMEDICAL JOURNAL (2015)
Programmed death ligand 1 expression and tumor-infiltrating lymphocytes in glioblastoma
Anna Sophie Berghoff et al.
NEURO-ONCOLOGY (2015)
The PD-1/B7-H1 Pathway Modulates the Natural Killer Cells versus Mouse Glioma Stem Cells
Bo Yuan Huang et al.
PLOS ONE (2015)
Association of PD-1, PD-1 Ligands, and Other Features of the Tumor Immune Microenvironment with Response to Anti-PD-1 Therapy
Janis M. Taube et al.
CLINICAL CANCER RESEARCH (2014)
Durable Therapeutic Efficacy Utilizing Combinatorial Blockade against IDO, CTLA-4, and PD-L1 in Mice with Brain Tumors
Derek A. Wainwright et al.
CLINICAL CANCER RESEARCH (2014)
B7-H3 and B7-H1 expression in cerebral spinal fluid and tumor tissue correlates with the malignancy grade of glioma patients
Aparajita Baral et al.
ONCOLOGY LETTERS (2014)
Immunologic checkpoints in cancer therapy: focus on the programmed death-1 (PD-1) receptor pathway
Parisa Momtaz et al.
PHARMACOGENOMICS & PERSONALIZED MEDICINE (2014)
Anti-PD-1 Blockade and Stereotactic Radiation Produce Long-Term Survival in Mice With Intracranial Gliomas
Jing Zeng et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2013)
PD-L1 Expression by Neurons Nearby Tumors Indicates Better Prognosis in Glioblastoma Patients
Yawei Liu et al.
JOURNAL OF NEUROSCIENCE (2013)
Safety and Activity of Anti-PD-L1 Antibody in Patients with Advanced Cancer
Julie R. Brahmer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Safety, Activity, and Immune Correlates of Anti-PD-1 Antibody in Cancer
Suzanne L. Topalian et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses
Andreas Stang
EUROPEAN JOURNAL OF EPIDEMIOLOGY (2010)
The PD-1 pathway in tolerance and autoimmunity
Loise M. Francisco et al.
IMMUNOLOGICAL REVIEWS (2010)
Survival comparison between glioblastoma multiforme and other incurable cancers
B. Tran et al.
JOURNAL OF CLINICAL NEUROSCIENCE (2010)
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement
David Moher et al.
PLOS MEDICINE (2009)
Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma
Andrew T. Parsa et al.
NATURE MEDICINE (2007)
The function of programmed cell death 1 and its ligands in regulating autoimmunity and infection
Arlene H. Sharpe et al.
NATURE IMMUNOLOGY (2007)
B7-homolog I expression by human glioma: a new mechanism of immune evasion
R Wilmotte et al.
NEUROREPORT (2005)
Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase
C Uyttenhove et al.
NATURE MEDICINE (2003)
Quantifying heterogeneity in a meta-analysis
JPT Higgins et al.
STATISTICS IN MEDICINE (2002)
Share Paper
